Peritoneal metastasis occurs when cancer cells detach from a primary tumor and implant on the peritoneum, the thin membrane lining the abdominal cavity and covering its organs. It represents one of the most challenging forms of cancer spread, historically treated as a terminal diagnosis with limited options. Since the 1980s, a shift in understanding has reframed peritoneal disease as a regional problem rather than a systemic one, opening the door to aggressive local treatments that can extend survival by years in selected patients. The biology behind how tumors reach and colonize the peritoneum, which cancers are most prone to doing so, and what factors shape outcomes are all interconnected and more nuanced than a simple “stage IV” label suggests.
How Cancer Cells Reach the Peritoneum
The most common route is transcoelomic spread, meaning cancer cells shed directly from a primary tumor into the peritoneal cavity. This is especially prominent in ovarian cancer, where it is the dominant mechanism of dissemination, though blood-borne and lymphatic spread also occur.1PubMed Central. Molecular Mechanisms Regulating Organ-Specific Metastases in Epithelial Ovarian Carcinoma In gastric and colorectal cancers, tumor cells can also penetrate the full thickness of the bowel wall and spill into the abdominal cavity once they breach the organ’s outer surface, a process called serosal invasion.
Once free-floating, cancer cells do not simply drift randomly. The peritoneal cavity is a single continuous space with interconnected regions, and fluid circulates through it in predictable patterns driven by gravity, breathing, and the movement of the diaphragm.2PubMed Central. The subperitoneal space and peritoneal cavity: basic concepts This circulation carries detached tumor cells to characteristic sites, particularly the pelvis (where fluid pools when a person is upright), the undersurface of the diaphragm, and the omentum, the fatty apron draped over the intestines.
For these floating cells to become actual metastases, they must stick to the peritoneal lining and invade the tissue beneath it. Two surface molecules play key roles in this initial attachment. Research on ovarian cancer cells showed that CD44 and beta-1 integrin mediate adhesion to mesothelial cells, with the mesothelial cells themselves producing the binding partners these molecules latch onto.3PubMed Central. CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells The same adhesion molecules were later shown to work in gastric and pancreatic cancer cells, where blocking both CD44 and beta-1 integrin with antibodies nearly completely prevented tumor cell attachment to the peritoneal surface in laboratory experiments.4PubMed. Adhesion of human gastric and pancreatic cancer cells to peritoneal mesothelial cells is mediated by CD44 and beta(1) integrin
Before and during this process, many tumor cells undergo a shift in their basic character called epithelial-mesenchymal transition. Cells that normally behave like stationary building blocks of organ tissue transform into something more mobile and invasive, adopting features that help them migrate and survive in a new environment.5PubMed Central. Research progress of epithelial-mesenchymal transformation-related transcription factors in peritoneal metastases This transformation is a recurring theme across many cancer types that develop peritoneal spread.
Why the Peritoneum Is Hospitable to Tumors
The peritoneum itself is not a strong physical barrier. Despite its appearance as a protective lining, the anatomic peritoneum is highly permeable to water, small molecules, and even proteins.6PubMed. The transport barrier in intraperitoneal therapy The real barrier is a complex structure of cells, connective tissue, and tiny blood vessels beneath the surface, not the membrane itself. This permeability, while relevant to drug delivery (more on that later), also means tumor cells face relatively little resistance when trying to implant.
Certain spots in the peritoneum are particularly vulnerable. The omentum contains clusters of immune cells called milky spots, tiny functional units scattered across its surface. Paradoxically, these immune structures serve as favorable landing sites for cancer cells, providing a microenvironment rich in growth factors and blood supply that supports tumor colonization rather than fighting it off.7PubMed Central. Milky spots: omental functional units and hotbeds for peritoneal cancer metastasis This is why the omentum is so frequently involved in peritoneal metastasis and why surgeons often remove it during cytoreductive procedures.
The primary tumor may also prepare distant peritoneal sites before cancer cells even arrive. In ovarian cancer, tumors release tiny extracellular vesicles called exosomes that travel ahead and reshape the peritoneal microenvironment, making it more receptive to incoming tumor cells.8PubMed Central. Exosomes promote pre-metastatic niche formation in ovarian cancer This “pre-metastatic niche” concept helps explain why peritoneal spread can be so widespread by the time it is detected: the ground has already been seeded.
Which Tumors Spread to the Peritoneum
Peritoneal metastasis is not equally common across all cancers. It clusters in tumors that arise within or adjacent to the abdominal cavity. Ovarian cancer is the most frequent culprit, with the majority of advanced cases involving peritoneal disease at diagnosis. Colorectal cancer, gastric cancer, and appendiceal tumors round out the main group. Rarer sources include pancreatic cancer, uterine cancer, and, occasionally, breast cancer.
Ovarian Cancer
Transcoelomic spread is the dominant route for epithelial ovarian cancer, and the disease has a strong affinity for the omentum, the pelvic peritoneum, and the undersurface of the diaphragm.1PubMed Central. Molecular Mechanisms Regulating Organ-Specific Metastases in Epithelial Ovarian Carcinoma Because ovarian cancer often presents late, many patients already have extensive peritoneal involvement at the time of their initial surgery. This makes ovarian cancer one of the cancers most commonly treated with combined surgical and intraperitoneal approaches.
Colorectal Cancer
Roughly 5 to 15 percent of colorectal cancer patients develop peritoneal metastasis, either at diagnosis or as a recurrence. Genomic profiling has revealed something striking about these tumors: peritoneal metastases from colorectal cancer overwhelmingly belong to a single molecular subtype known as CMS4, characterized by stromal infiltration and activated pathways related to tissue remodeling and inflammation. One study found that virtually all peritoneal metastases sampled were classified as CMS4, and the expression of CMS4-defining genes was significantly higher in the peritoneal deposits than in the primary tumors themselves.9British Journal of Cancer. Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity A separate analysis comparing over 600 primary colorectal tumors to nearly 350 peritoneal metastases found that certain common colorectal mutations, like those in APC and TP53, were less frequent in peritoneal deposits, while others like GNAS were enriched in mucinous peritoneal tumors specifically.10PubMed Central. Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma These molecular differences matter because they suggest peritoneal disease is not simply a copy of the original tumor but a biologically distinct entity that may respond differently to treatment.
Gastric Cancer
The peritoneum is the most common site of recurrence after gastric cancer surgery. Signet-ring cell carcinoma, a particularly aggressive subtype, carries a peritoneal metastasis rate of about 20 percent and is an independent risk factor for poor prognosis.11PubMed Central. CRS + HIPEC combined with IP + IV chemotherapy for gastric signet-ring cell carcinoma: Case report of long-term survival When signet-ring cell gastric cancer does spread to the peritoneum, outcomes with aggressive surgical treatment remain grim, and complete tumor removal is often not achievable.12Journal of Gastric Cancer. Initial Clinical Experience with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Signet-Ring Cell Gastric Cancer with Peritoneal Metastases Other risk factors for peritoneal spread in gastric cancer include lymph node involvement, deep invasion of the stomach wall, and younger age at diagnosis.
Appendiceal Tumors and Pseudomyxoma Peritonei
Appendiceal mucinous tumors occupy a unique niche. They can produce a condition called pseudomyxoma peritonei, where the peritoneal cavity fills with gelatinous mucinous material studded with tumor cells. This condition arises from a spectrum of appendiceal tumors ranging from borderline to outright malignant.13PubMed Central. Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei A consensus of international experts has defined pseudomyxoma peritonei as a clinical entity characterized by mucinous ascites, omental cake, peritoneal implants, and sometimes ovarian involvement, generally originating from the appendix.14PubMed Central. Pathophysiology and classification of pseudomyxoma peritonei Despite its frightening appearance, low-grade pseudomyxoma peritonei tends to be one of the more treatable forms of peritoneal disease when managed at specialized centers.
Primary Peritoneal Cancers vs. Secondary Spread
Not all peritoneal cancer is metastatic. The peritoneum itself can give rise to primary malignancies. Diffuse malignant peritoneal mesothelioma, linked to asbestos exposure, originates from the mesothelial cells lining the peritoneal cavity. Distinguishing it from secondary carcinomatosis (cancer that has spread from elsewhere) matters enormously for treatment, but the two can look similar on imaging. CT imaging studies have identified distinguishing features: mesothelioma tends to cause smooth, confluent peritoneal thickening, omental cake, and mesenteric involvement, while secondary carcinomatosis more often presents with discrete peritoneal nodules and fused lymph nodes.15PubMed. CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis When imaging is ambiguous, specialized staining during tissue biopsy can resolve the question, since mesothelioma is strongly positive for certain markers like calretinin and CK 5/6 that adenocarcinomas are not.16Radiology Case Reports. Diffuse malignant peritoneal mesothelioma mimicking ovarian cancer
Detection and Staging
Peritoneal metastasis is notoriously difficult to detect early. Small implants on the peritoneal surface do not show up well on standard CT scans, and even experienced radiologists can miss them. A CT scoring system developed for gastric cancer achieved a sensitivity of about 88 percent and specificity of 76 percent for detecting occult peritoneal metastasis, but that still means roughly one in eight cases is missed.17PubMed Central. Four-Point Computed Tomography Scores for Evaluation of Occult Peritoneal Metastasis in Patients with Gastric Cancer This is why staging laparoscopy, where a surgeon inserts a camera into the abdomen, remains the gold standard for confirming peritoneal disease in cancers like gastric cancer before committing to a major operation.
The most widely used tool for quantifying the extent of peritoneal disease is the Peritoneal Cancer Index, or PCI. The abdomen is divided into 13 regions, and each region is scored from 0 to 3 based on the size of the largest tumor deposit, yielding a total score from 0 to 39. The PCI is a powerful predictor of whether surgeons can achieve a complete tumor removal. In ovarian cancer, one study found that the PCI predicted incomplete surgery with an area under the curve of 0.94, meaning it was an excellent discriminator. A PCI of 24 or lower had 100 percent sensitivity for identifying cases where complete removal was possible, but many patients above that threshold were still operable, with about two-thirds achieving complete surgery. Above a PCI of 33, only about 29 percent of patients had successful complete operations.18PubMed Central. The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer A separate study confirmed the PCI’s strong predictive value, with the optimal cutoff for predicting incomplete surgery at a PCI of 20 in their cohort, yielding 89 percent sensitivity and 92 percent specificity.19International Journal of Gynecological Cancer. The peritoneal cancer index as a predictor of complete cytoreduction at primary and interval cytoreductive surgery in advanced ovarian cancer
Liquid Biopsy of Peritoneal Fluid
Emerging approaches aim to catch peritoneal disease even earlier using molecular analysis of the fluid within the abdominal cavity. In gastric cancer patients, tumor-guided cell-free DNA analysis of peritoneal fluid detected peritoneal disease with 91 percent sensitivity, compared to just 64 percent for conventional cytology (examining the fluid under a microscope for cancer cells). Two patients whose peritoneal wash fluid contained cell-free DNA but no visible cancer cells went on to develop overt peritoneal disease within six months.20PubMed. Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid Another study found that patients who were positive for both circulating tumor DNA and circulating tumor cells in peritoneal lavage fluid after surgery had dramatically higher recurrence risk, with hazard ratios above 18 for the postoperative combined test.21PubMed. Effectiveness of circulating tumor cells and circulating tumor DNA in peritoneal lavage fluid for predicting metachronous peritoneal metastasis of gastric cancer These techniques are still largely investigational, but they suggest a future where peritoneal recurrence could be predicted months before it becomes visible.
Treatment Approaches
The modern treatment framework for peritoneal metastasis traces back to Paul Sugarbaker, who in the 1980s proposed that peritoneal cancer should be treated as a locoregional problem. His paradigm combined maximal surgical removal of visible tumor (cytoreductive surgery, or CRS) with heated chemotherapy bathed directly inside the abdomen (hyperthermic intraperitoneal chemotherapy, or HIPEC) to mop up microscopic residual disease.22Journal of Comprehensive Surgery. Evaluation of cytoreductive surgery and the HIPEC approach in peritoneal metastases from Sugarbaker to the present day with current evidence
The logic behind HIPEC exploits the peritoneum’s permeability characteristics. Because the peritoneal surface allows drugs through while the deeper tissue barrier slows their absorption into the bloodstream, chemotherapy delivered directly into the abdominal cavity maintains much higher drug concentrations at the tumor surface compared to intravenous delivery, while producing lower levels of systemic toxicity.23PubMed Central. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers The heat component adds to this effect: hyperthermia boosts the cancer-killing power of several chemotherapy drugs and improves how deeply they penetrate into tissue.24PubMed Central. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy
A newer technique called pressurized intraperitoneal aerosol chemotherapy, or PIPAC, takes a different approach. Instead of flooding the abdomen with heated liquid, chemotherapy is delivered as a fine aerosol during laparoscopy. The increased abdominal pressure during the procedure may enhance how deeply the drug penetrates into peritoneal tissue.25PubMed. Intraperitoneal aerosolized drug delivery: Technology, recent developments, and future outlook PIPAC is less invasive than CRS plus HIPEC and is increasingly used as a palliative or bridging treatment for patients who are not candidates for full cytoreductive surgery.
Immunotherapy
The peritoneal cavity has historically been considered an immunologically suppressed environment, which partly explains why tumor cells thrive there. Efforts to overcome this include delivering immune-based treatments directly into the abdomen. Catumaxomab, an antibody targeting EpCAM (a molecule found on many epithelial tumor cells), was authorized in Europe for treating malignant ascites and demonstrated real clinical benefit in reducing fluid accumulation. Beyond antibodies, early-stage research with CAR-T cells delivered directly into the peritoneal cavity has shown promise in animal models, where a single injection eradicated established ovarian cancer tumors and significantly extended survival.26PubMed Central. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis Other approaches under investigation include combining intraperitoneal immune checkpoint inhibitors with CAR-T cells and using dendritic cell vaccines to stimulate the body’s own anti-tumor immune responses within the peritoneal space.27PubMed Central. Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes
What Determines Prognosis
Prognosis in peritoneal metastasis depends less on a single variable than on a constellation of factors, but one stands above the rest: completeness of cytoreduction. Whether surgeons can remove all visible tumor is consistently the strongest predictor of survival across tumor types. In one single-center analysis, patients who underwent complete cytoreduction had dramatically better outcomes, with the completeness of cytoreduction score emerging as a highly significant independent factor alongside serum albumin levels and postoperative complication rate.28PubMed Central. Survival prognostic factors in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: analysis from a single oncological center
The PCI score, which quantifies how widespread the disease is, directly correlates with the likelihood of achieving complete surgery and with long-term survival. In colorectal peritoneal metastasis, a large study of 555 patients treated with CRS and HIPEC reported a 5-year overall survival of 51 percent following complete cytoreduction. Disease-free survival was lower at 31 percent, reflecting the high recurrence rate even after seemingly successful surgery. A PCI above 6, positive lymph nodes, and perineural invasion were all independently associated with worse outcomes.29PubMed. Survival Analysis and Recurrence Patterns in 555 Patients with Colorectal Peritoneal Metastases Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy An earlier study likewise identified a PCI of 10 or below, complete cytoreduction, well-differentiated tumor histology, and limited small bowel involvement as independent favorable prognostic factors.30PubMed Central. Prognostic Factors of Peritoneal Metastases from Colorectal Cancer following Cytoreductive Surgery and Perioperative Chemotherapy
These numbers represent carefully selected patients treated at experienced centers, so they should not be taken as representative of all patients with peritoneal metastasis. Many patients are not candidates for CRS and HIPEC due to the extent of their disease, poor general health, or unfavorable tumor biology, and their prognosis is significantly worse.
Malignant Ascites and Bowel Obstruction
Two complications dominate the clinical picture of advanced peritoneal disease and profoundly affect quality of life. Malignant ascites, the accumulation of fluid in the abdominal cavity, develops when peritoneal tumors stimulate blood vessel leakiness through production of vascular endothelial growth factor (VEGF). This molecule is a direct driver of fluid accumulation, and its levels in ascites fluid correlate with disease progression in gastric and ovarian cancers.31PubMed Central. VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody Repeated drainage procedures offer temporary relief, and anti-VEGF therapies can reduce fluid re-accumulation in some patients.
Malignant bowel obstruction is the other dreaded complication, occurring when tumor deposits compress or infiltrate the intestines enough to block them. The decision about whether to operate is genuinely difficult. A systematic review of palliative surgery for malignant bowel obstruction from carcinomatosis found that while surgery could provide short-term symptom relief, it carried high rates of serious complications, frequent re-obstruction, and prolonged hospitalization. The review emphasized that surgeons should have frank conversations with patients about whether the potential short-term palliation aligns with their goals, given the substantial morbidity and the fact that surgery’s impact on overall quality of life remains poorly understood.32PubMed Central. Palliative Surgery for Malignant Bowel Obstruction from Carcinomatosis: A Systematic Review Non-surgical management with medications, bowel rest, and sometimes stenting is often the more appropriate path, particularly in patients with widespread peritoneal disease and limited life expectancy.
The Role of Specialized Centers
One of the most practical takeaways from the peritoneal metastasis literature is the importance of where treatment happens. CRS combined with HIPEC is a complex, lengthy operation with significant morbidity. The 5-year survival figures reported in the literature come predominantly from high-volume centers where surgical teams perform these procedures routinely. Complication rates, completeness of cytoreduction, and survival outcomes all tend to be better at centers with more experience. Patients diagnosed with peritoneal disease from colorectal, ovarian, gastric, or appendiceal cancers benefit from referral to a peritoneal surface malignancy program, where multidisciplinary teams can assess whether aggressive treatment is appropriate or whether a palliative approach would better serve the patient’s goals. The gap between what is achievable at a specialized center and what happens at a low-volume hospital is among the largest in surgical oncology, making referral patterns a genuinely life-altering decision point.